AUPH Q2 2023 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+47.2% YoY

Gross Profit

$40M96.2% margin

Operating Income

-$16M-39.0% margin

Net Income

-$11M-27.7% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+20.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$549M

Total Liabilities

$157M

Stockholders' Equity

$392M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$28M	+47.2%
Gross Profit	$40M	$27M	+50.2%
Operating Income	-$16M	-$36M	+55.1%
Net Income	-$11M	-$36M	+67.6%

Revenue Segments

Product

$41M99%

License, Royalty and Collaboration Revenue

$394,0001%